Back to User profile » Dr Monica Canciani
Papers published by Dr Monica Canciani:
Corrigendum
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum]
Ponzetti C, Canciani M, Farina M, Era S, Walzer S
ClinicoEconomics and Outcomes Research 2017, 9:75-76
Published Date: 17 January 2017
Original Research
![Noteworthy comment: In oncology an important parameter of safety is the potential treatment error in hospitals. The hypothesis which is being analyzed in the underlying work is the potential benefit of hospitals from a safety reduction through fix-dose subcutaneous therapies in comparison to intravenous therapies with trastuzumab and rituximab.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Administrative risk quantification of subcutaneous and intravenous therapies in Italian centers utilizing the Failure Mode and Effects Analysis approach
Ponzetti C, Canciani M, Farina M, Era S, Walzer S
ClinicoEconomics and Outcomes Research 2016, 8:353-359
Published Date: 3 August 2016
Original Research
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey
Ponzetti C, Canciani M, Farina M, Era S, Walzer S
ClinicoEconomics and Outcomes Research 2016, 8:227-233
Published Date: 23 May 2016